Impact of metformin & serratiopeptidase in obese patients with knee osteoarthritis
- Knee osteoarthritis is a common disabling chronic disease globally. Many pharmacological agents have been used efficiently in treatment of knee osteoarthritis.
- Technology Benefits
- This study aims to evaluate metformin &serratiopeptidase together in treatment and stop of osteoarthritis progression by different mechanisms
- Technology Application
- Present study was a randomized clinical trial study conducted in Al-Kindi teaching hospital through the period from 1st January to 30th of May, 2017 on two groups of 80 osteoarthritis patients (group I; treated with metformin 850 mg oral tablets) and (group II; treated with metformin 850 mg oral tablets & serratiopepitidase 20 mg oral tablets). Parameters of two groups were compared with those of 40 normal healthy controls
- Detailed Technology Description
- A total of 80 patients with knee OA were selected non-randomly and were randomized digitally into two groups (group I; treated with metformin 850 mg oral tablets) and (group II; treated with metformin 850 mg oral tablets & serratiopepitidase 20 mg oral tablets). The patients with knee OA were diagnosed clinically and radiological by Rheumatologist in Al-Kindi teaching hospital. A group of 40 healthy controls was selected from relatives of patients. The weight and height of each all study participants (n=120) was measured using calibrated scale to calculate the body mass index (BMI) before selection in the study. All the study participants were matched for BMI.
- Type of Cooperation
- Application Date
- from 1st January to 30th of May, 2017
- No CN patents
For more information, please click Here